Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments

Shingo Koyama, Yoshiki Sekijima, Masatsune Ogura, Mika Hori, Kota Matsuki, Takashi Miida and Mariko Harada-Shiba on behalf of the Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan

1 Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan
2 Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
3 Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan
4 Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
5 Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan
6 Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Aomori, Japan
7 Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
8 Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan

The Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan: Mariko Harada-Shiba (Division of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan), Shun Ishibashi (Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University, Tochigi, Japan), Shinji Yokoyama (Institute for Biological Functions, Chubu University, Aichi, Japan), Hitoshi Shimano (Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine University of Tsukuba, Tsukuba, Japan), Koutaro Yokote (Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan), Hideaki Bujo (Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Chiba, Japan), Shizuya Yamashita (Rinku General Medical Center, Osaka, Japan), Kazuhiisa Tsukamoto (Department of Internal Medicine, Teikyo University, Tokyo, Japan), Toshio Hayashi (School of Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan), Katsunori Ikewaki (Division of Neurology, Anti-Aging, and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan), Takanari Gotoda (Department of Metabolic Biochemistry, Faculty of Medicine, Kyorin University, Tokyo, Japan), Kazushige Dobashi (Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan), Yoshihiro Miyamoto (Open Innovation Center, National Cerebral and Cardiovascular Center, Osaka, Japan), Misa Takegami (Department of Preventive and Epidemiology, National Cerebral and Cardiovascular Center, Osaka, Japan), Yoshiki Sekijima (Division of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan), Yasushi Ishigaki (Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan), Hiromi Okazaki (Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan), Atsushi Nohara (Ishikawa Prefectural Central Hospital, Kanazawa, Japan), Shingo Koyama (Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan), Kyoko Inagaki (Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Nippon Medical School, Tokyo, Japan), Koh Ono (Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan), Masahiro Kochi (Division of Cardiovascular Medicine, Department of Medicine, Osaka University Graduate School of Medicine, Osaka, Japan), Hirohisa Daida (Faculty of Health Science, Juntendo University, Juntendo University Graduate School of Medicine, Tokyo, Japan), Manabu Takahashi (Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan), Kimitoshi Nakamura (Department of Pediatrics, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan), Takashi Miida (Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan), Masaaki Kawashiri (Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan), Tetsuo Minamino (Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan), Sachiko Okazaki (Division for Health Service Promotion, The University of Tokyo, Tokyo, Japan), Hayato Tada (Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan), Jun Wada (Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan), Masatsune Ogura (Division of Lipid Metabolism, Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan), Hirotoshi Ohmura (Department of Cardiovascular Medicine, School of Medicine, Juntendo University, Tokyo, Japan), Mika Hori (Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan), Kota Matsuki (Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Japan).

Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: March 21, 2021 Published online: May 8, 2021
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disorder caused by mutations in the CYP27A1 gene, which encodes the mitochondrial enzyme sterol 27-hydroxylase. Decreased sterol 27-hydroxylase activity results in impaired bile acid synthesis, leading to reduced production of bile acids, especially chenodeoxycholic acid (CDCA), as well as elevated serum cholestanol and urine bile alcohols. The accumulation of cholestanol and cholesterol mainly in the brain, lenses, and tendons results in the characteristic clinical manifestations of CTX. Clinical presentation is characterized by systemic symptoms including neonatal jaundice or cholestasis, refractory diarrhea, juvenile cataracts, tendon xanthomas, osteoporosis, coronary heart disease, and a broad range of neuropsychiatric manifestations. The combinations of symptoms vary from patient to patient and the presenting symptoms, especially in the early disease phase, may be nonspecific, which leads to a substantial diagnostic delay or underdiagnosis. Replacement of CDCA has been approved as a first-line treatment for CTX, and can lead to biochemical and clinical improvements. However, the effect of CDCA treatment is limited once significant neuropsychiatric manifestations are established. The age at diagnosis and initiation of CDCA treatment correlate with the prognosis of patients with CTX. Therefore, early diagnosis and subsequent treatment initiation are essential.

Key words: Cerebrotendinous xanthomatosis, CTX, CYP27A1, Cholestanol, Chenodeoxycholic acid

Introduction

Cerebrotendinous xanthomatosis (CTX: OMIM#213700), first described by van Bogaert et al. in 1937, is a rare autosomal-recessive lipid storage disease caused by deficiency of the mitochondrial cytochrome P 450 enzyme, sterol 27-hydroxylase (CYP27A1, EC 1.14.15.15) due to mutations in the CYP27A1 gene\(^1\). Clinical presentation is characterized by neonatal jaundice or cholestasis, refractory diarrhea, juvenile cataracts, tendon xanthomas, osteoporosis, coronary heart disease, and progressive neuropsychiatric disturbances including mental retardation or dementia, psychiatric symptoms, pyramidal and cerebellar signs, peripheral neuropathy, extrapyramidal manifestations, and seizures\(^2,9\). CTX is associated with considerable variability in clinical manifestations among patients and even within the same family\(^9\). The broad and diverse clinical symptoms cause a substantial diagnostic delay\(^2,4,9\). Replacement treatment with chenodeoxycholic acid (CDCA) in the early stage of the disease has been reported to improve or even prevent clinical symptoms of CTX\(^10,11\); however, after significant neurological pathology is established, the effect of the treatment is limited and deterioration of clinical manifestations may continue\(^3,8,12,13\). Therefore, it is crucial to treat CTX patients at the initial stage of the disease. In this article, we provide the current understanding of the underlying pathomechanisms, clinical manifestations, diagnosis, and treatment of CTX.

Pathophysiology

CTX is caused by mutations in the CYP27A1 gene encoding sterol 27-hydroxylase, a key enzyme in the bile acid synthesis pathway. A schematic

---

Address for correspondence: Yoshiki Sekijima, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
E-mail address: sekijima@shinshu-u.ac.jp

Received: March 17, 2021 Accepted for publication: March 21, 2021

Copyright 2021 Japan Atherosclerosis Society
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.

Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: March 21, 2021 Published online: May 8, 2021
cholesterol and bile alcohols\(^\text{16}\). Elevated serum cholestanol and urine bile alcohols are the biochemical diagnostic hallmarks in CTX. Consequently, increased cholesterol metabolites, such as cholestanol, accumulate mainly in the brain, lenses, and tendons, leading to the characteristic clinical manifestations of CTX. Elevated levels of cholestanol have been found in the serum and tissues, including those of the central nervous system, tendon xanthomas, and atheromatous lesions, in CTX patients. Although the cholestanol-to-cholesterol ratios of various tissues were higher than that of serum, cholesterol was more abundant than cholestanol in both serum and tissues\(^\text{17}\). Cholestanol is widely used as a diagnostic marker but the usefulness of 7α-hydroxy-4-cholesten-3-one as a precursor for

representation of the bile acid synthesis pathway is shown in Fig. 1. The classical pathway is initiated by 7α-hydroxylation of cholesterol, catalyzed by the rate-limiting enzyme cholesterol 7α-hydroxylase. The alternative pathway is initiated by 27-hydroxylation of cholesterol, which is catalyzed by sterol 27-hydroxylase. Decreased activity of sterol 27-hydroxylase leads to impaired bile acid synthesis in both the classical and alternative pathways\(^\text{14}\), resulting in reduced production of bile acids, especially CDCA, and to a lesser extent cholic acid\(^\text{15}\). The absence of a negative feedback effect of CDCA on cholesterol 7α-hydroxylase accelerates these metabolic abnormalities, leading to increased levels of the bile acid intermediate 7α-hydroxy-4-cholesten-3-one as a precursor for cholestanol and bile alcohols\(^\text{16}\). Elevated serum cholestanol and urine bile alcohols are the biochemical diagnostic hallmarks in CTX. Consequently, increased cholesterol metabolites, such as cholestanol, accumulate mainly in the brain, lenses, and tendons, leading to the characteristic clinical manifestations of CTX. Elevated levels of cholestanol have been found in the serum and tissues, including those of the central nervous system, tendon xanthomas, and atheromatous lesions, in CTX patients. Although the cholestanol-to-cholesterol ratios of various tissues were higher than that of serum, cholesterol was more abundant than cholestanol in both serum and tissues\(^\text{17}\). Cholestanol is widely used as a diagnostic marker but the usefulness of 7α-hydroxy-4-cholesten-3-one as a precursor for

---

**Fig. 1.** Impaired bile acid synthesis in cerebrotendinous xanthomatosis (CTX)

In CTX, mutations in the \textit{CYP27A1} gene lead to sterol 27-hydroxylase deficiency, resulting in reduced production of chenodeoxycholic acid and upregulation of the rate-limiting enzyme in the bile acid synthesis pathway, cholesterol 7α-hydroxylase. Increased levels of serum cholestanol and urinary bile alcohols are biological markers in CTX. HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA.
quantification in both the diagnosis and monitoring of CTX has also been reported. It has also been shown that quantification of a panel of plasma ketosterol bile acid precursors (7α-hydroxy-4-cholesten-3-one, 7α,12α-dihydroxy-4-cholesten-3-one, and 7α,12α-dihydroxy-5β-cholastan-3-one) provides a more sensitive biochemical approach when compared with measurement of cholesterol.

In 1968, Menkes et al. discovered accumulation of cholesterol and cholesterin in the cerebrum and cerebellum of patients with CTX. Although the mechanism by which cholestanol accumulates in the brain remains unclear, one possible explanation is that the bile acid precursor 7α-hydroxy-4-cholesten-3-one, which passes through the blood-brain barrier (BBB) more efficiently than cholestanol, can be converted to cholestanol by neurons, astrocytes, microglia, and human monocyte-derived macrophages. Another possible explanation is impairment of the BBB. Increased levels of cholestanol and apolipoprotein B were observed in the cerebrospinal fluid of patients with CTX, indicating disrupted function of the BBB. It has also been proposed that large plasma bile acid glucose uronides play a role in the abnormal BBB permeability in CTX, leading to increased transport of cholestanol and cholesterol in the brain.

Although the major pathway for production of cholestanol in CTX has been clarified, little is known about its metabolism. Under normal conditions, the 7α-hydroxy-4-cholesten-3-one-dependent pathway accounts for only about 30% of cholestanol biosynthesis in the brain, and cerebral cholestanol is mainly formed from cholesterol. Using Cyp27a1 and Cyp46a1 knockout mice, Mast et al. demonstrated that CYP46A1 plays an important role in cholestanol removal from the brain and that CYP27A1 deficiency results in a preferential increase in cholestanol in the cerebellum.

CTX patients develop premature atherosclerosis and xanthomas despite normal serum cholesterol concentrations. However, abundant deposits of cholesterol are detected in addition to cholestanol in the respective lesions in CTX. Although the mechanism leading to premature arteriosclerosis and tendon xanthomas in CTX remains unclear, reduced capacity for reverse cholesterol transport has been proposed as a possible cause. Sterol 27-hydroxylase, which is expressed in macrophages, endothelial cells, and tenocytes as well as in the liver, seems to contribute to the transport of peripheral cholesterol to the liver by transforming intracellular cholesterol into 27-hydroxycholesterol, which has a higher capacity for passing through lipophilic membranes compared with cholesterol. In addition, 27-hydroxycholesterol is an endogenous ligand for liver X receptor (LXR). LXR activation induces upregulation of ATP-binding cassette transporter A1 (ABCA1) expression, leading to increased cholesterol efflux. Fu et al. demonstrated that upregulation of ABCA1 in response to cholesterol loading was impaired in primary fibroblasts derived from a CTX patient. In addition, since 27-hydroxycholesterol was found to be the major oxysterol in human atherosclerotic lesions, extrahepatic sterol 27-hydroxylase is thought to be an anti-atherosclerotic enzyme. Absence of the two above defense mechanisms may contribute to premature atherosclerosis and xanthoma formation in CTX.

Epidemiology

CTX patients have been reported worldwide but prevalence of the disease is considered to be underestimated. Based on the carrier frequency of the pathogenic CYP27A1 c.1183C>T (p.R395C) mutation in 115 control subjects, the prevalence of CTX in the USA among Caucasians of European ancestry was estimated to be 3-5:100,000 individuals. Pilo-de-la-Fuente et al. estimated a minimum prevalence of 1/1,800,000 individuals in Spain. Estimates of the incidence of CTX vary among locations. A recent genetic epidemiological study based on the Exome Aggregation Consortium (ExAC) cohort, a large cohort of over 60,000 unrelated subjects, evaluated the allele frequency of 57 known and 29 predicted CTX-causing variants and estimated the incidence of CTX to be 1:134,970-1:461,358 in Europeans, 1:263,222-1:468,624 in Africans, 1:71,677-1:148,914 in Americans, 1:64,247-1:64,712 in East Asians, and 1:36,072-1:75,601 in South Asians. Prevalence among Jews of Moroccan origin and the Druze sect in Israel has been reported to be particularly high.

Molecular Genetics

In 1991, human sterol 27-hydroxylase cDNA was isolated from a liver cDNA library. The CYP27A1 gene consists of nine exons and eight introns and spans 18.6 kb of DNA on chromosome 2q33-qter. Sterol 27-hydroxylase consists of a 33-residue mitochondrial signal sequence followed by a mature protein of 498 amino acids containing putative binding sites for heme and adrenodoxin. Cali et al. first identified two CYP27A1 missense mutations, p.R395C and p.R479C, in patients with CTX and demonstrated that a loss-of-function mechanism is responsible for CTX. CYP27A1 is the only gene known to be
Clinical Features

Clinical Phenotypes

Clinical presentation of CTX is characterized by diverse systemic and neuropsychiatric manifestations and combinations of symptoms vary from patient to patient. Systemic symptoms include neonatal jaundice or cholestasis, chronic diarrhea, juvenile cataracts, xanthomas, osteoporosis, and coronary heart disease. The neurological and psychiatric manifestations of CTX vary widely. Intellectual disability as well as pyramidal and cerebellar signs are the most frequent and are cardinal clinical features. In addition, CTX patients can present with extrapyramidal manifestations, peripheral neuropathy, epilepsy, and psychiatric disturbances. Autonomic involvement has also been reported.

A representative clinical course of classical form CTX, the most common form of this condition, is shown in Fig. 2. Patients with classical form CTX develop neuropsychiatric symptoms attributed to the cerebrum, cerebellum, and/or brainstem, in combination with various systemic manifestations. The concept of spinal form CTX, also called spinal xanthomatosis, was proposed by Virrips et al. in 1999. Patients exhibit clinical symptoms and signs related to involvement of the corticospinal tracts and dorsal columns of the spinal cord, without intellectual impairment, cerebellar signs, or peripheral neuropathy, at the time of presentation of the spinal cord syndrome. Although most patients with spinal form

Fig. 2. Representative clinical course of classical form CTX
Figure shows typical ages of onset of CTX-related symptoms.
CTX also exhibit various systemic and neurological symptoms, spinal form CTX without other neurological manifestations has been reported\(^4\). Spinal form CTX has a relatively mild clinical course compared with classical form CTX\(^5\).

We have proposed non-neurological form CTX\(^6\) as another clinical phenotype. Although patients with the non-neurological form may develop neurological symptoms later in life, two genetically confirmed CTX patients in their fifties showed no evidence of neurological manifestations \(\geq \) 20 years after disease onset. Therefore, we regarded the non-neurological form as a distinct clinical phenotype of CTX\(^7\).

All CTX patients exhibit increased serum cholestanol levels at the time of diagnosis\(^2\). While a significant relationship between serum cholestanol and clinical phenotype or disability was not detected\(^8\), Sekijima et al. showed that classical form patients had significantly higher levels of cholestanol than spinal form patients\(^9\).

**Systemic Manifestations/Neonatal Jaundice or Cholestasis**

Prolonged neonatal jaundice or cholestasis could be the earliest clinical presentation of CTX\(^7\). Laboratory findings have revealed conjugated hyperbilirubinemia with raised transaminases and alkaline phosphatase, whereas levels of \(\gamma\)-glutamyl transferase were normal or minimally elevated\(^9\), which is the characteristic feature of inborn errors of bile acid synthesis\(^1\). In one study, hepatomegaly or hepatosplenomegaly was evident\(^1\). Liver biopsy specimens have revealed nonspecific chronic active hepatitis with giant cell transformation, piecemeal or focal bridging necrosis, and fibrosis, in addition to intralobular cholestasis\(^2\). Cirrhosis was detected in an explanted liver\(^5\). In addition, retrospective cohort studies have demonstrated that about 8–16% of patients had a past medical history of neonatal cholestatic jaundice\(^2\). Cataracts are arguably an important cue for early diagnosis of CTX. A screening for CTX among 170 patients with idiopathic bilateral cataracts diagnosed \(\leq \) 20 years after disease onset identified 3 cases\(^7\). In addition to cataracts, ophthalmological manifestations include optic neuropathy with optic disc paleness, premature retinal vessel sclerosis, and cholesterol-like deposits\(^8\). Optic neuropathy with features suggestive of optic neuritis has also been reported\(^9\).

**Systemic Manifestations/Xanthomas**

Xanthomas usually appear during the second or third decade of life. They typically occur on the Achilles tendon, but may be found on the elbow, neck, knee, and the bottom of the foot (Fig. 3). The patellar and finger extensor tendons are also common sites for development of tendon xanthomas\(^1\). Xanthomas in the lung\(^1\) and choroid plexus have also

**Systemic Manifestations/Chronic Diarrhea**

Chronic unexplained diarrhea begins in infancy and continues into adulthood. It may be the earliest symptom of CTX and could start within the first year of life\(^1\). Gastrointestinal tract investigations in patients with diarrhea did not produce any abnormal findings\(^1\). Also, rectal biopsy did not demonstrate any accumulation of cholestrol or cholesterol and fatty acids could not be detected in the feces\(^1\). Usually, diarrhea ceases immediately after starting treatment with CDCA\(^1\). Although the pathogenesis of diarrhea is still unclear, presence of bile alcohol in the lumen of the gut and/or intraluminal deficiency of CDCA are the most likely causes\(^1\).
Skeletal deformities including kyphosis, pectus excavates, pes equinovarus, and pes cavus were found in CTX patients and Ginanneschi et al. reported that pes cavus occurrence was not significantly different in groups with and without peripheral nerve abnormalities.

**Systemic Manifestations/Cardiovascular System Involvement**

Premature atherosclerosis and cardiovascular disease have been reported as systemic manifestations in CTX patients even in their thirties. Myocardial infarction is a cause of premature death in this condition. Kuriyama et al. reviewed 144 cases of CTX and reported that 15 patients (10.4%) had cardiovascular disease, consisting of coronary artery disease in ten patients, ischemic changes on electrocardiogram in four, and mitral valve insufficiency in one patient. Coronary artery disease was evident in 8 of 40 CTX patients (20%) in a nationwide survey on CTX in Japan. In this survey, the mean age at onset of coronary artery disease was 52.5 ± 5.8 years (mean ± standard deviation (SD)). Duell et al. reported that 3 of 43 CTX patients (7%) had premature cardiovascular disease, consisting of myocardial infarction in two patients, and angina pectoris in one patient in the USA. Abdominal aortic aneurysm, coronary artery dissection, aneurysmal coronary artery disease, advanced carotid atherosclerotic lesions, and thickening of the interatrial septum compatible with lipomatous hypertrophy have also been reported in CTX.

**Systemic Manifestations/Pulmonary Involvement**

Elevated levels of cholestanol in bronchoalveolar lavage fluid as well as in serum have been reported in CTX patients without pulmonary symptoms, or radiological and pulmonary function abnormalities. Transbronchial lung biopsy specimens have revealed foamy macrophages and small granulomas in alveolar septa.

**Neuropsychiatric Manifestations/Intellectual disability**

Among CTX patients, 48–74% present with intellectual disability, which is one of the most frequent neurological symptoms. It is particularly important to take developmental delays, mental retardation, and learning difficulties beginning in childhood into consideration for early diagnosis of CTX. CDCA treatment has been shown to improve bone mineral density (BMD). Skeletal deformities including kyphosis, pectus excavates, pes equinovarus, and pes cavus were found in CTX patients and Ginanneschi et al. reported that pes cavus occurrence was not significantly different in groups with and without peripheral nerve abnormalities.

**Systemic Manifestations/Skeletal System Involvement**

Osteoporosis and increased bone fractures are CTX-associated systemic manifestations. However, the underlying pathogenesis of osteoporosis in this condition is still unknown. Decreased levels of serum 25-hydroxyvitamin D were detected in CTX patients. In contrast, however, Federico et al. reported that levels of 25-hydroxyvitamin D were substantially within the normal range, indicating that a deficiency in vitamin D metabolites may not be the only factor responsible for the development of osteoporosis in CTX. An alternative hypothesis for explaining the cause of osteoporosis is impairment of intestinal calcium absorption due to changes in the quantity and composition of bile acids. In general, osteoporosis has been considered to occur in the later stages of the disease. However, teenage CTX patients could have early osteoporosis and a history of bone fracture. CDCA treatment has been shown to improve bone mineral density (BMD).
of patients with CTX remains undetermined, a fronto-temporal dementia phenotype exhibiting behavioral and personality changes, extensive cerebral cortex symptoms including left-right disorientation, constructional apraxia, and temporal and spatial disorientation in addition to frontal lobe dysfunction, and a corticobasal syndrome phenotype have been reported.

Neuropsychiatric Manifestations/Pyramidal and Cerebellar Signs

Pyramidal and/or cerebellar signs typically emerge in the third or fourth decade and lead to gait disturbance in CTX patients. Pyramidal and cerebellar signs have been detected in 64–92% and 36–83% of patients with CTX, respectively. Pyramidal signs such as spasticity, hyperreflexia, and extensor plantar response can be cardinal clinical signs especially in patients with spinal form CTX. Owing to dorsal column involvement, simultaneous occurrence of impaired position and vibration sensation in the lower extremities can lead to spastic-ataxic gait in this form. Mignarri et al. have reported the usefulness of transcranial magnetic stimulation in detecting corticospinal tract damage. Cerebellar signs include nystagmus, ataxic dysarthria, as well as limb and truncal ataxia. Pyramidal signs frequently coexist with cerebellar signs.

Neuropsychiatric Manifestations/Extrapyramidal Manifestations

CTX patients can present with a wide range of movement disorders including parkinsonism, dystonia, myoclonus, and postural tremor. When movement disorders are diagnosed, patients have a tendency to present with other CTX-associated systemic and neuropsychiatric manifestations. Parkinsonism usually occurs later in life and is the most frequently reported type of movement disorder in CTX, followed by dystonia, myoclonus, and postural tremor. Parkinsonism seems to be a treatment-resistant feature in CTX, with CDCA treatment seemingly having no effect. In addition, CTX patients may develop parkinsonism during treatment with CDCA. The effect of L-dopa is controversial. In addition to the characteristic brain MRI findings of CTX, signal hyperintensities on T2-weighted images in the substantia nigra, globus pallidus, and striatum have been described and functional dopaminergic imaging has demonstrated a pre-synaptic dopaminergic deficit in CTX patients presenting with parkinsonism. Although movement disorders are considered a late disease manifestation, Zubarioglu et al. reported that all six patients who were diagnosed before 18 years of age had intention tremor.

Neuropsychiatric Manifestations/Peripheral Nervous System Involvement

Peripheral neuropathy is an established clinical feature of CTX; however, it is still being debated whether the underlying pathogenesis of CTX-related polyneuropathy is demyelinating or axonal in origin. Based on the presence of onion bulbs, which are generally considered a hallmark of chronic demyelination, the pathological process has been interpreted as demyelinating. The other hand, Verrips et al. reported that axonal degeneration was the predominant process on the basis of nerve conduction velocity (NCV) studies and sural nerve biopsy specimens showing features of axonal degeneration. In addition to axonal polyneuropathy and demyelination polyneuropathy, a mixed type of neuropathy has been reported, indicating that CTX could exhibit any type of neuropathy. CTX-related polyneuropathy seems to be predominantly motor neuropathy. Although neurophysiologically confirmed neuropathy frequently occurs in CTX, signs and symptoms related to polyneuropathy are often absent or difficult to appreciate because central nervous system involvement may dominate the clinical picture. The disease severity of polyneuropathy varies greatly among patients, ranging from asymptomatic presentations to severe polyneuropathy. Thickening of the nerve roots and trunks of the lumbosacral plexus or cauda equina has been reported.

Neuropsychiatric Manifestations/Muscle Involvement

Controversy exists regarding whether muscle involvement is a characteristic feature in CTX. Federico et al. noted mild myopathic changes, while Verrips et al. reported that muscle biopsies demonstrated neurogenic changes without any definite myopathic characteristics. The results for mitochondrial respiratory chain enzymatic activity are also controversial. Abnormal findings from ultrastructural studies of muscles include changes in the mitochondria and membranous system, and an increased amount of lipid droplets, lipofuscin, and glycogen; however, the significance of these findings remains to be determined.

Neuropsychiatric Manifestations/Epilepsy

In CTX, 10–33% of patients have epileptic seizures. Epilepsy can develop at any stage in life and is often seen in the early phase of the disease.
Epilepsy could be a diagnostic cue in some cases\textsuperscript{114-116}. A CTX patient presenting with infantile spasms has also been reported, but this is a rare case\textsuperscript{117}. Electroencephalographic abnormalities are frequently observed in cases of CTX even without clinical signs of seizures\textsuperscript{11, 118}. In addition to slow background activity composed of theta and delta waves, bursts of high voltage slow activity are frequently demonstrated. Spike and sharp wave complexes can also be detected\textsuperscript{10, 11, 118}. CDCA treatment leads to improvement or normalization of electroencephalographic findings\textsuperscript{10, 11, 60, 118}, and epilepsy in CTX seems to respond well to anti-epileptic agents\textsuperscript{12, 114-116, 119}. CDCA treatment could lead to improved seizure control\textsuperscript{12, 60, 120}, even in patients with drug-resistant epilepsy\textsuperscript{121}.

**Neuropsychiatric Manifestations/Behavioral manifestations**

Psychiatric and behavioral manifestations include personality changes with irritability and aggressivity, depression, delusional syndrome, catatonia, psychosis, attention-deficit hyperactivity disorder, oppositional-defiant disorder, and autism spectrum disorder\textsuperscript{13, 122}. Behavioral disorders and affective/mood disorders associated with learning difficulties or mental retardation appearing during childhood or adolescence should lead to biochemical investigations to exclude CTX.

**Radiological, Pathological, and Neurophysiological Examinations**

**Neuroimaging**

The most distinctive neuroradiological findings are signal hyperintensities on T2-weighted and/or FLAIR images in the dentate nuclei and adjacent cerebellar white matter\textsuperscript{123, 124}. Abnormal signal changes in the dentate nuclei can be more clearly detected on FLAIR images than on T2-weighted images\textsuperscript{123}. It was found that abnormal hyperintensities on T2-weighted and/or FLAIR images could be detected in the globus pallidus, internal capsules (arrowheads in B), cerebral peduncles (arrows in C), and dentate nuclei (arrows in D). Diffuse cerebral (A) and cerebellar (D) atrophy are evident. Sagittal T2-weighted image of the spinal cord exhibiting longitudinally extensive hyperintense lesions (arrows in E). Axial T2-weighted image at the C3 level showing involvement of lateral corticospinal tracts (arrowheads in F) and gracile tracts (arrow in F).

Poor prognosis in CTX\textsuperscript{127, 128}, while absence of dentate nuclei signal alteration is considered an indicator of a better prognosis\textsuperscript{128}. Furthermore, calcifications were detected in the dentate nuclei in a subgroup of patients\textsuperscript{128}. Supratentorial and/or infratentorial atrophy are also observed\textsuperscript{123, 124, 126} (Fig. 4). Cortical volume, rather than white matter volume, was correlated with clinical status and cortical atrophy could be detected in all neocortical regions, with a preference for the fronto-parietal cortex\textsuperscript{126}. In addition, cerebellar vacuolation, which is detected as hypointense lesions on both T1-weighted and FLAIR images, has been recently indicated as a marker of a
hyperintense lesions involving lateral corticospinal tracts and gracile tracts on T2-weighted images\(^{40, 44-46}\). It is noteworthy that absence of signal changes on spinal cord MRI cannot rule out the possibility of spinal cord CTX\(^{42, 43}\).

On magnetic resonance spectroscopy (MRS), decreases in N-acetylaspitate (NAA) intensities and increases in lactate signals point to axonal damage and brain mitochondrial dysfunction, respectively\(^{72}\). In addition to decreased NAA intensities, lipid peaks were evident on MRS using a short TE\(^{129}\). Increased levels of myo-inositol indicate gliosis and astrocytic proliferation\(^{129, 130}\).

Cerebellar glucose hypometabolism in \(^{18}\)F-2-deoxy-2-fluoro-glucose positron emission tomography (FDG-PET) and cerebellar hypoperfusion in single photon emission computed tomography (SPECT) with \(^{99m}\)Tc-ethylcysteinate dimer (ECD) have been reported despite normal cerebellar morphology\(^{88, 131, 132}\). In addition to in the cerebellum, SPECT using \(^{99m}\)Tc- ECD and \(^{123}\)I-N-isopropyl-p-iodoamphetamine (\(^{123}\)I-IMP) revealed cerebral hypoperfusion, predominantly in the fronto-parietal lobes\(^{88, 89, 132}\). Gray matter atrophy patterns were correlated with hypoperfusion in SPECT using \(^{99m}\)Tc- ECD\(^{133}\).

Diffusion tensor imaging (DTI) revealed that fractional anisotropy (FA) reduction preceded structural alterations detected by voxel-based morphometry and correlated with cognitive function\(^{139}\). Widespread reductions of FA and decreased track-density were demonstrated\(^{120, 134}\).

Neuropathology
At macroscopic examination, nonspecific brain and cerebellar atrophy and a yellowish soft tissue in the cerebellum, cerebrum, choroid plexus, cerebral peduncles, and globus pallidus were observed\(^{135-138}\). In the cerebral peduncles, cystic necrosis of the corticospinal tracts has been reported\(^{139}\). Microscopic examinations have revealed lipid crystal clefts, neuronal loss, demyelination, reactive astrogliosis, and foamy macrophages in the affected regions, especially in the dentate nucleus and surrounding area, as well as in the cerebrum, basal ganglia, brainstem, and spinal cord\(^{65, 124, 135-139}\). In patients with spinal cord involvement, extensive symmetric loss of myelin and axons was detected particularly in the lateral corticospinal tracts and gracile tracts of the spinal cord\(^{40}\).

Neurophysiological Examinations
In addition to NCV studies and electroencephalography, abnormalities have been found in neurophysiological examinations. The P100 peak latency of visual evoked potentials (VEPs) was delayed\(^{109, 140, 141}\) and the I to III, III to V, and I to V interpeak latencies of brain stem evoked potentials (BAEPs) were prolonged\(^{109, 140, 141}\). Central conduction time in somatosensory evoked potentials (SEEPs)\(^{109, 142}\) and motor evoked potentials (MEPs)\(^{89, 91, 141}\) were increased, with lower extremity predominance.

Diagnosis
Importance of Early Diagnosis and Treatment
CTX is a treatable metabolic disorder; however, once significant neurological symptoms are established, clinical deterioration can occur despite normalization of cholestanol levels after treatment with CDCA\(^{3}\). Even with therapy, only 28% of the patients remained stable, whereas 60% continued to deteriorate and 20% died, in a cohort of 25 patients with CTX in Spain\(^3\). Duell et al. reported that clinical deterioration during follow up was observed in patients who had significant neurological symptoms when they were diagnosed at the age of 25 years or older\(^8\). Yahalom et al. and Stelten et al. have shown that the age of diagnosis and initiation of CDCA treatment correlates with the prognosis of patients with CTX\(^{12, 13}\). Berginer et al. reported two siblings with CTX who began CDCA treatment from 2 and 7 years of age, respectively, and did not develop any neurological manifestations during a 14-year follow-up period\(^{152}\). These findings strongly suggest that early diagnosis and treatment are crucial in CTX. However, retrospective cohort studies on CTX have revealed a substantial diagnostic delay of 15–25 years\(^{2-4, 9}\).

Juvenile cataracts are usually the earliest clinical sign that precedes tendon xanthomas and neurological symptoms. Crueysberg et al. emphasized that the combination of juvenile cataracts and chronic diarrhea is noteworthy in the early diagnosis of CTX\(^{143}\). It is recommended that all patients with cataracts before the age of 30 years are screened for CTX, especially if they also have CTX-related conditions such as chronic diarrhea, tendon xanthomas, and/or neuropsychiatric symptoms\(^8\). Verrips et al. emphasized that presence of tendon xanthomas is not obligatory for a diagnosis of CTX and recommended that presence of two of the four clinical features of premature cataracts, intractable diarrhea, progressive neurological signs and symptoms, and tendon xanthomas prompt thorough biochemical screening for CTX\(^{68}\). It is also important to consider intellectual disability, usually presenting at school age, for early diagnosis of CTX\(^9\). In addition, because affected relatives may be asymptomatic, biochemical examination of all siblings of a patient with CTX is recommended\(^2, 4\).
The presence of biallelic mutations in the \textit{CYP27A1} gene.

**Differential Diagnosis**

Differential diagnosis of CTX differs substantially according to presenting symptoms. Inborn errors of bile acid metabolism including CTX lead to neonatal cholestasis or hepatitis\cite{144, 145}, which can be the first manifestation in this disease. In patients with juvenile bilateral cataracts and/or progressive mental deterioration, CTX should be considered\cite{2, 57}. When xanthomas are evident, differential diagnosis includes familial hypercholesterolemia (FH) and sitosterolemia. FH is characterized by elevated levels of LDL cholesterol, the presence of tendon xanthomas, and premature coronary artery disease, and mutations in \textit{LDLR}, \textit{APOB}, and \textit{PCSK9} have been reported to cause FH\cite{146}. Sitosterolemia is an autosomal recessive sterol storage disorder characterized by elevated levels of LDL cholesterol and plant sterols such as sitosterol and campesterol, tendonous and tuberous xanthomas, and premature atherosclerosis. It is caused by biallelic mutations in either \textit{ABCG5} or \textit{ABCG8}\cite{147}. The presence of juvenile cataracts, chronic unexplained diarrhea, and progressive neuropsychiatric manifestations can distinguish CTX from these two disorders. Other

### Table 1. Diagnostic criteria for cerebrotendinous xanthomatosis (Sekijima \textit{et al.}\cite{9})

| Category | A. Symptoms |
|----------|-------------|
| Definite | 1. Tendon xanthoma |
|          | 2. Progressive neurological dysfunction\textsuperscript{a} or mental retardation |
|          | 3. Juvenile cataract |
|          | 4. Juvenile coronary artery disease |
|          | 5. Chronic unexplained diarrhea |
|          | 6. Juvenile osteoporosis |
|          | 7. Prolonged neonatal cholestasis |

| B. Biochemical finding |
|------------------------|
| Elevated serum cholestanol level |

| C. Genetic testing |
|--------------------|
| Pathogenic mutation in \textit{CYP27A1} gene (homozygosity or compound heterozygosity) |

| D. Differential diagnosis |
|---------------------------|
| Increased serum cholestanol level due to following diseases should be excluded |
| - Familial hypercholesterolemia |
| - Sitosterolemia |
| - Obstructive biliary tract disease |
| - Hypothyroidism |

| Diagnostic category |
|---------------------|
| Definite: At least one of symptom in A and B+C+D |
| Probable: At least one of symptom in A and B+D |
| Possible: At least one of symptom in A and B |

\textsuperscript{a}Representative progressive neurological dysfunction includes cognitive dysfunction, cerebellar symptoms, pyramidal symptoms, extrapyramidal symptoms, seizure, peripheral neuropathy, and sensory disturbance attributed to spinal cord.

To identify and treat CTX patients at an initial stage of the disease, Mignarri \textit{et al.} created a suspicion index and developed a diagnostic algorithm for early diagnosis of CTX\cite{9}. Their suspicion index comprised weighted scores assigned to indicators such as family history characteristics and common systemic and neurological symptoms. They suggested that their proposed algorithm would be useful for early diagnosis, even in patients before the onset of disabling neurological symptoms including ataxia, spasticity, and psychiatric disturbances\cite{4}.

**Diagnostic Criteria**

In the absence of generally accepted diagnostic criteria for CTX, we recently proposed new diagnostic criteria with emphasis on early diagnosis (Table 1)\cite{9}. They include clinical symptoms, biochemical findings, genetic analysis, and differential diagnosis. We established three diagnostic categories in accordance with levels of certainty: definite, probable, and possible CTX. The diagnosis of possible CTX is made when there is at least one CTX-related clinical symptom and elevated levels of serum cholestanol (≥ 4.5 µg/mL, mean ± SD: 2.35 ± 0.73 µg/mL). Excluding other conditions with elevated levels of cholestanol is necessary for diagnosis of probable CTX. A definite diagnosis of CTX is confirmed by

\textbf{Advance Publication Journal of Atherosclerosis and Thrombosis}

\textbf{Accepted for publication: March 21, 2021    Published online: May 8, 2021}
conditions with elevated levels of cholestanol include obstructive biliary tract diseases and hypothyroidism. In patients with cerebellar ataxia, CTX patients might be misdiagnosed as spinocerebellar atrophy, multiple system atrophy, or Marinesco-Sjögren syndrome. CTX should be included in the differential diagnosis of spastic paraplegia.

**Clinical Management**

CDCA has been approved as first-line treatment for CTX. In a landmark study published in 1984, Bergner et al. demonstrated the long-term efficacy of oral CDCA treatment. In addition to a decrease in serum cholestanol and elimination of abnormal urinary and biliary excretion of bile alcohols, CDCA treatment led to an improvement in electroencephalographic findings and neurological manifestations including intellectual impairment, pyramidal and cerebellar signs, and peripheral neuropathy. CDCA treatment is recommended at a dose of 750 mg/day for adults and 15 mg/kg/day for children in three divided oral doses. It has been shown to result in a gradual decline in serum cholestanol during the first 2 years. Assessment of cholestanol levels may be useful in monitoring patient adherence to treatment. However, it should be noted that a decreased level of cholestanol does not necessarily suggest a good prognosis.

In Japan, CDCA has been approved for dissolution of gallstones, but not for the treatment of CTX.

Although CDCA is a relatively safe drug, gastrointestinal manifestations and drug-induced liver damage may occur. Huidikoper et al. reported an infantile patient with CTX who developed jaundice with hepatomegaly within 6 weeks after initiating CDCA administration at a dosage of 15 mg/kg/day. After treatment with CDCA was stopped, liver size and function rapidly normalized. CDCA supplementation was then restarted and maintained at 5 mg/kg/day with no further evidence of liver dysfunction and adequate metabolic control. Duell et al. reported that 9% of patients required dose adjustment for CDCA owing to moderate drug-induced liver damage. These findings suggest that clinical and laboratory monitoring and dosage adjustment for CDCA are essential in the treatment of CTX, especially in infants and young children.

CDCA was initially preferred to cholic acid because it was more effective in reducing cholesterol 7α-hydroxylase and had a stronger negative feedback effect on it. Cholic acid has been shown to be effective in the treatment of other genetic defects in bile acid synthesis. Since CDCA is intrinsically hepatotoxic, cholic acid is considered the safer option in CTX, especially in infancy. Mandia et al. reported potential efficacy for cholic acid in adult patients with CTX, including individuals whose CDCA treatment was discontinued due to supply difficulties. Treatment with cholic acid not only significantly reduced cholestanol levels in all patients but also led to improvement or stabilization of systemic and/or neurological manifestations. No adverse effects were reported in patients undergoing cholic acid treatment, suggesting that cholic acid may be a suitable alternative treatment, especially in patients with adverse effects related to CDCA, such as drug-induced liver damage.

Treatment with ursodeoxycholic acid, which does not inhibit cholesterol 7α-hydroxylase, has been shown to be ineffective. When ursodeoxycholic acid was substituted for CDCA, plasma cholestanol returned to pretreatment levels.

The effectiveness of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (statins) remains controversial. Lewis et al. reported that mevinolin normalized serum cholestanol and reduced the size of xanthomas, whereas Batta et al. found that lovastatin did not affect abnormal bile acid synthesis or reduce plasma cholestanol levels. Although synergistic effects of combination therapy with CDCA and HMG-CoA reductase inhibitors on serum cholestanol or urine bile alcohols have been observed, absence of an additive effect has also been reported.

After switching from combined therapy of CDCA and HMG-CoA reductase inhibitors to HMG-CoA reductase inhibitor monotherapy, clinical symptoms such as xanthomas and neurological manifestations, and electroencephalographic findings were re-exacerbated with reappearance of abnormal bile alcohol excretion or elevated plasma cholestanol. Therefore, HMG-CoA reductase inhibitors could be beneficial when combined with CDCA, but long-term clinical benefits should be proven.

Low-density lipoprotein (LDL) is a major carrier of serum cholestanol. LDL-apheresis, usually combined with CDCA and HMG-CoA reductase inhibitors, has been performed to reduce serum cholestanol. Levels of serum cholestanol or 7α-hydroxy-4-cholesten-3-one decreased after each LDL-apheresis, but returned to their initial levels within 1–2 weeks, suggesting that LDL-apheresis at a frequency of at least once every 2 weeks is necessary. The effects of LDL-apheresis on clinical manifestations are still controversial despite the decrease in cholestanol. In addition, the invasiveness of this procedure and its necessity for the long-term management of the disease should be taken into account.
account\(^{61}\).

Symptomatic treatments for epilepsy\(^{115, 120}\), psychiatric manifestations\(^{122}\), and movement disorders such as dystonia\(^{97, 98}\) and parkinsonism\(^{90, 95}\) should be considered. Cataract extraction is also usually required\(^{57}\).

After treatment with CDCA, improvements in neurophysiological examinations including NCV studies\(^{78}\), VEP\(^{72, 78}\), SSEP\(^{72}\), MEP\(^{72, 91}\), and EEG\(^{10, 11}\) have been reported. Besides conventional MRI, DTI and tractography, MRS, and SPECT imaging might have potential as neuroimaging modalities for monitoring treatment response\(^{120, 132-134, 162, 163}\).

**Conclusions and Perspectives**

CTX is considered a rare inherited metabolic disorder. However, it may be under- or misdiagnosed, although effective treatment is available. There is a crucial “point of no return” in CTX, after which treatment initiation can no longer prevent the progression of the disease\(^{12}\). The earlier the diagnosis is made and the sooner treatment is started, the more likely it is that the significant neurological manifestations that diminish the quality of life of patients with CTX can be improved or even prevented. Neonatal jaundice, chronic unexplained diarrhea, developmental delays, mental retardation, and learning difficulties are non-specific symptoms, but they could be diagnostic cues for pediatricians. Ophthalmologists have an opportunity to diagnose CTX, because bilateral cataracts are one of the earliest clinical symptoms and juvenile-onset bilateral cataracts could be useful as a screening marker for CTX\(^{57}\).

Furthermore, it could be beneficial to screen newborns for CTX in the future\(^{164}\).

**Acknowledgments and Notice of Grant Support**

This work has been supported by Health, Labour and Welfare Sciences Research Grant for Research on Rare and Intractable Diseases (H30-nanji-ippan-003).

**Conflicts of Interest**

Atsushi Nohara has nothing to disclose. Hayato Tada has nothing to disclose. Masatsune Ogura has received honoraria from Amgen Inc., Astellas Pharma Inc. Sachiko Okazaki has received scholarship grants from Minophagen Pharmaceutical Co., Ltd., Kowa Company, Ltd. Koh Ono has nothing to disclose. Hitoshi Shimano has nothing to disclose. Hiroyuki Daida has received honoraria from Amgen Inc., Daiichi-Sankyo Co., Ltd., Kowa Co., Ltd., and MSD K.K., Novartis Pharma K.K., Bayer Yakuhin, Ltd. and received clinical research funding from Canon Medical Systems Corporation, Philips Japan, Ltd., Toho Holdings Co., Ltd., Asahi Kasei Corporation, and Inter Reha Co., Ltd. HD has also received scholarship grants from Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., MSD K.K., Daiichi-Sankyo Co., Ltd., Pfizer Co., Ltd., Mitsubishi Tanabe Pharma Corp., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Teijin Pharma, Ltd., Shionogi & Co., Ltd., Actelion Pharmaceuticals, Ltd., Actelion Ltd., Kowa Co., Ltd., Bayer Yakuhin, Ltd. HD has also courses endowed by companies, including Philips Japan, Ltd., ResMed, Fukuda Denshi Co., Ltd., and Paramount Bed Co., Ltd. Kazushige Dobashi has nothing to disclose. Toshio Hayashi has nothing to disclose. Mika Hori has nothing to disclose. Kota Matsu has nothing to disclose. Tetsuo Minamino has nothing to disclose. Shinji Yokoyama has nothing to disclose. Mariko Harada-Shiba has received stock holdings or options from Liid Pharma, honoraria from Amgen Inc., Astellas Pharma Inc., Sanofi, and scholarship grants from Aegerion Pharmaceuticals, Inc., Recordati Rare Diseases Japan, and Kaneka Corporation. Katsunori Ikewaki has nothing to disclose. Yasushi Ishigaki has nothing to disclose. Shun Ishibashi has received honoraria from Kowa Co., Ltd. and a scholarship grant from Ono Pharmaceutical Co., Ltd. Kyoko Inagaki has nothing to disclose. Hiroto Ohmura has nothing to disclose. Hiroaki Okazaki has received scholarship grants from Minophagen Pharmaceutical Co., Ltd., Kowa Company, Ltd. Masa-aki Kawashiri has nothing to disclose. Masayuki Kuroda has nothing to disclose. Masahiro Koseki has received clinical research funding from Kowa Company, Ltd., Rohto Pharmaceutical Co., Ltd., Takenari Gotoda has nothing to disclose. Shingo Koyama has nothing to disclose. Yoshiki Sekijima has nothing to disclose. Manabu Takahashi has nothing to disclose. Yasuo Takeuchi has nothing to disclose. Misa Takegami has nothing to disclose. Kazuhi Tsukamoto has received honoraria from Bayer Yakuhin, Ltd., MSD Ltd., Takeda Pharmaceutical Company Ltd. and scholarship grants from Mitsubishi Tanabe Pharma Corporation, Bayer Yakuhin, Ltd., Sanofi K.K., Atsuko Nakatsuka has nothing to disclose. Kimitoshi Nakamura has nothing to disclose. Satoshi Hirayama has nothing to disclose. Tetsuo Minamino has nothing to disclose. Hideaki Bujo has nothing to disclose. Daisaku Masuda has received clinical research funding from MSD K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kowa Co., Ltd. Takashi Miida has nothing to disclose. Yoshiiro
Miyamoto has nothing to disclose. Takeyoshi Murano has nothing to disclose. Takashi Yamaguchi has nothing to disclose. Shizuya Yamashita has received honoraria from Kowa Company, Ltd., MSD K.K. Masashi Yamamoto has nothing to disclose. Kouataro Yokote has received honoraria from Kowa Company, Ltd., MSD K.K., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corp., Amgen K.K., Takeda Pharmaceutical Company Limited, Sanofi K.K., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Daiichi-Sankyo Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Taisho Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and received clinical research funding from Taisho Pharmaceutical Co., Ltd. KY has also received scholarship grants from Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co., Ltd., MSD K.K., Pfizer Japan Inc., Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co., Ltd., Kao Corporation, Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Daiichi-Sankyo Co., Ltd., Teijin Pharma, Ltd., Shionogi Co., Ltd., Bayer Yakuhin, Ltd. Jun Wada has nothing to disclose.

References

1) Cali JJ, Hsieh CL, Francke U, Russell DW: Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem, 1991; 266: 7779-7783
2) Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabreëls FJ, van Engelen BG, van den Heuvel LP: Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain, 2000; 123: 908-919
3) Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, Duarte J, Muñiz-Pérez S, Sobrido MJ: Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol, 2011; 18: 1203-1211
4) Mignarri A, Gallus GN, Dotti MT, Federico A: A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis, 2014; 37: 421-429
5) Nie S, Chen G, Cao X, Zhang Y: Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis, 2014; 9: 179
6) Salen G, Steiner RD: Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis, 2017; 40: 771-781
7) Wong JC, Walsh K, Hayden D, Eichler FS: Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis, 2018; 41: 647-656
8) Duell PB, Salen G, Eichler FS, DeBarber AE, Connor SL, Casaday L, Jaydev S, Kisanuki Y, Lekprasert P, Malloy MJ, Ramdhani RA, Ziajka PE, Quinn JF, Su KG, Geller AS, Diffenderfer MR, Schaefer EJ: Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol, 2018; 12: 1169-1178
9) Sekijima Y, Koyama S, Yoshinaga T, Koiuma M, Inaba Y: Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet, 2018; 63: 271-280
10) Berginer VM, Salen G, Shefer S: Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med, 1984; 311: 1649-1652
11) van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ: Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr, 1998; 157: 313-316
12) Yahalom G, Tsarabi R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S: Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol, 2013; 36: 78-83
13) Stelten BML, Huijdekoper HH, van de Warrenburg BPC, Brilstra EH, Hollak CEM, Haak HR, Kluftjimans LAJ, Wevers RA, Verrips A: Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology, 2019; 92: e83-e95
14) DeBarber AE, Luo J, Star-Weinstock M, Purkayastha S, Geraghty MT, Chiang JP, Merkens LS, Pappu AS, Steiner RD: A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns. J Lipid Res, 2014; 55: 146-154
15) Salen G: Cholesterol deposition in cerebrotendinous xanthomatosis. A possible mechanism. Ann Intern Med, 1971; 75: 843-851
16) Björkhem I, Skrede S, Buchmann MS, East C, Grundy S: Accumulation of 7 alpha-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: effect of treatment with chenodeoxycholic acid. Hepatology, 1987; 7: 266-271
17) Bhattacharryya AK, Lin DS, Connor WE: Cholesterol metabolism in patients with cerebrotendinous xanthomatosis: absorption, turnover, and tissue deposition. J Lipid Res, 2007; 48: 185-192
18) DeBarber AE, Connor WE, Pappu AS, Merkens LS, Steiner RD: ESI-MS/MS quantification of 7alpha-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis. Clin Chim Acta, 2010; 41: 43-48
19) DeBarber AE, Luo J, Giugliani R, Souza CF, Chiang JP, Merkens LS, Pappu AS, Steiner RD: A useful multi-analyte blood test for cerebrotendinous xanthomatosis. Clin Biochem, 2014; 47: 860-863
20) Menkes JH, Schimschock JR, Swanson PD: Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol, 1968; 19: 47-53
21) Panzenboeck U, Andersson U, Hansson M, Sattler W,
Meaney S, Björkhem I: On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J Lipid Res, 2007; 48: 1167-1174

22) Båvner A, Shafaiati M, Hansson M, Olin M, Shipitzen S, Meiner V, Leitersdorf E, Björkhem I: On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase. J Lipid Res, 2010; 51: 2722-2730

23) Salen G, Berginer V, Shore V, Horak I, Horak E, Tint GS, Shefer S: Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med, 1987; 316: 1233-1238

24) Batt AK, Salen G, Shefer S, Tint GS, Batt M: Increased plasma bile alcohol glucuronides in patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid. J Lipid Res, 1987; 28: 1006-1012

25) Mast N, Anderson KW, Lin JB, Li Y, Turko IV, Tatsuoka C, Björkhem I, Pikuleva IA: Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum. J Biol Chem, 2017; 292: 4913-4924

26) Babiker A, Andersson O, Lund E, Xiu RJ, Deeb S, Reshef A, Leitersdorf E, Diczfalusy U, Björkhem I: Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem, 1997; 272: 26253-26261

27) von Bahr S, Movin T, Papadogiannakis N, Pikuleva I, Rönnow P, Diczfalusy U, Björkhem I: Mechanism of accumulation of cholestanol and cholestanol in tendons and the role of sterol 27-hydroxylase (CYP27A1). Arterioscler Thromb Vasc Biol, 2002; 22: 1129-1135

28) Björkhem I, Andersson O, Diczfalusy U, Sevastik B, Xiu RJ, Duan C, Lund E: Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A, 1994; 91: 8592-8596

29) Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG: 27-Hydroxylcholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells. J Biol Chem, 2001; 276: 38378-38387

30) Tall AR, Costet P, Wang N: Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest, 2002; 110: 899-904

31) Marengo B, Bellora F, Ricciarelli R, De Ciacus C, Furfaro A, Leardi R, Colla R, Pacini D, Traverso N, Moreta A, Pronzato MA, Bottino C, Domenicotti C: Oxysterol mixture and, in particular, 27-hydroxycholesterol drive M2 polarization of human macrophages. Biofactors, 2016; 42: 80-92

32) Lorincz MT, Rainier S, Thomas D, Fink JK: Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol, 2005; 62: 1459-1463

33) Appadurai V, DeBarber A, Chiang PW, Patel SB, Steiner RD, Tyler C, Bonnen PE: Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab, 2015; 116: 298-304

34) Berginer VM, Abelovich D: Genetics of cerebrotendinous xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in Sephardim of Moroccan origin. Am J Med Genet, 1981; 10: 151-157

35) Falik-Zaccii TC, Kfir N, Frenkel P, Cohen C, Tanus M, Mandel H, Shihab S, Morkos S, Aaref S, Summar ML, Khayat M: Population screening in a Druze community: the challenge and the reward. Genet Med, 2008; 10: 903-909

36) Cali JJ, Russell DW: Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem, 1991; 266: 7774-7778

37) Leitersdorf E, Reshef A, Meiner V, Levitzki R, Schwartz SP, Dann EJ, Berkmann N, Cali JJ, Klapholz L, Berginer VM: Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. J Clin Invest, 1993; 91: 2488-2496

38) Gallus GN, Dotti MT, Federico A: Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci, 2006; 27: 143-149

39) Chen SF, Tsai NW, Chang CC, Lu CH, Huang CR, Chuang YC, Chang WN: Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. BMC Neurol, 2011; 11: 63

40) Verrips A, Nijeholt GJ, Barkhof F, Van Engelen BG, Wesseling P, Luyten JA, Wevers RA, Starn J, Wokke JH, van den Heuvel LP, Keyser A, Gabrels FJ: Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain, 1999; 122: 1589-1595

41) Bartholdi D, Zumsteg D, Verrips A, Wevers RA, Sistermans E, Hess K, Jung HH: Spinal phenotype of cerebrotendinous xanthomatosis--a pitfall in the diagnosis of multiple sclerosis. J Neurol, 2004; 251: 105-107

42) Nicholls Z, Hobson E, Martindale J, Shaw PJ: Diagnosis of spinal xanthomatosis by next-generation sequencing: identifying a rare, treatable mimic of hereditary spastic paraparesis. Pract Neurol, 2015; 15: 280-283

43) Saute JA, Giugliani R, Merkens LS, Chiang JP, DeBarber AE, de Souza CF: Look carefully to the heels! A potentially treatable cause of spastic paraplegia. J Inherit Metab Dis, 2015; 38: 363-364

44) Abe R, Sekijima Y, Kinoshita T, Yoshinaga T, Koyama S, Kato T, Ikeda SI: Spinal form cerebrotendinous xanthomatosis--a variant of cerebrotendinous xanthomatosis. J Neurol Sci, 2006; 239: 105-107

45) Hanashiro S, Sawada M, Ishikawa Y, Shiraga N, Ikeda K, Am J Med Genet, 1981; 10: 151-157

46) Saygı S, Elibol B: Diagnostic challenge: A case of late-onset spinal form xanthomatosis without brain lesion: a case report. BMC Neurol, 2016; 16: 21

47) Mutlu D, Tuncer A, Gocmen R, Yalcin-Cakmakli G, Saygi S, Elbilb B: Diagnostic challenge: A case of late-
onset spinal form cerebrotendinous xanthomatosis.
Neurology, 2019; 92: 438-439

47) Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R: Mutations in the sterol 27-hydroxylation gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis, 2002; 25: 501-513

48) von Bahr S, Björkhem I, Van’t Hooff F, Alvelius G, Nemeth A, Sjövall J, Fischler B: Mutation in the sterol 27-hydroxylation gene associated with fatal cholestasis in infancy. J Pediatr Gastroenterol Nutr, 2005; 40: 481-486

49) Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P: Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis, 2008; 31: S241-S245

50) Gong JY, Setchell KDR, Zhao J, Zhang W, Lu Y, Lackner K, Knisely AS, Wang NL, Hao CZ, Zhang MH, Wang JS: Severe Neonatal Cholestasis in Cerebrotendinous Xanthomatosis: Genetics, Immunostaining, Mass Spectrometry. J Pediatr Gastroenterol Nutr, 2017; 65: 561-568

51) Sundaram SS, Bove KE, Lovell MA, Sokol RJ: Mechanisms of disease: Inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol, 2008; 5: 456-468

52) Edwards PA, Kast HR, Anisfeld AM: BAREing it all: the adopted of LXRs and FXR and their roles in lipid homeostasis. J Lipid Res, 2002; 43: 2-12

53) Degos B, Nadjar Y, Amador Mdel M, Lamari F, Sedel F, Roze E, Couvert P, Mochel F: Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. Orphanet J Rare Dis, 2016; 11: 41

54) van Heijst AF, Wevers RA, Tangerman A, Cruysberg JR, Renier WO, Tolboom JJ: Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Paediatr, 1996; 85: 932-936

55) McKenna P, Morgan SJ, Bosanquet RC, Laker MF: A case of cerebrotendinous xanthomatosis. II: The sterol content of a cataractous lens. Br J Ophthalmol, 1990; 74: 629-630

56) Tibrewal S, Duell PB, DeBarber AE, Loh AR: Cerebrotendinous xanthomatosis: early diagnosis on the basis of juvenile cataracts. J AAPOS, 2017; 21: 505-507

57) Freedman SF, Brennard C, Chiang J, DeBarber A, Del Monte MA, Duell PB, Fiorito J, Marshall R: Prevalence of Cerebrotendinous Xanthomatosis Among Patients Diagnosed With Acquired Juvenile-Onset Idiopathic Bilateral Cataracts. JAMA Ophthalmol, 2019; Epub ahead of print

58) Dotti MT, Ruffa A, Federico A: Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings. J Inherit Metab Dis, 2001; 24: 696-706

59) Miyamoto M, Ishii N, Mochizuki H, Shiomi K, Kaida T, Chuman H, Nakazato M: Optic Neuropathy with Features Suggestive of Optic Neuritis in Cerebrotendinous Xanthomatosis. Case Rep Neurol Med, 2019; 2019: 2576826

60) Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis
cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int, 2013; 92: 282-286.

75) Zübbaroğlu T, Bilen İP, Kiyikım E, Doğan BB, Enver EÖ, Cansever MS, Zeybek AÇA: Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis. Turk Pediatri Ars, 2019; 54: 113-118.

76) Federico A, Dotti MT, Loref, Nuti R: Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci, 1993; 115: 67-70.

77) Zübbaroğlu T, Kiyikım E, Yesil G, Demircioğlu D, Cansever MS, Yalcinkaya C, Aktuglu-Zeybek C: Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey. Acta Neurol Belg, 2019; 119: 343-350.

78) Ginanneschi F, Mignarri A, Mondelli M, Gallus GN, Del Puppo M, Giorgi S, Federico A, Rossi A, Dotti MT: Polynuropath in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol, 2013; 260: 268-274.

79) Kuriyama M, Fujiyama J, Yoshidome H, Takenaga S, Matsumuro K, Kasama T, Fukuda K, Kuramoto T, Hoshita T, Seyama Y, Okatu Y, Osame M: Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neurol Sci, 1991; 102: 225-232.

80) Fujiyama J, Kuriyama M, Arima S, Shibata Y, Nagata K, Takenaga S, Tanaka H, Osame M: Atherogenic risk factors in cerebrotendinous xanthomatosis. Clin Chim Acta, 1991; 200: 1-11.

81) Burnett JR, Moses EA, Croft KD, Brown AJ, Grainger K, Vaskaran SD, Leitersdorf E, Watts GF: Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta, 2001; 306: 63-69.

82) Valdivielso P, Calandra S, Durán JC, Gerutti R, Herrera E, González P: Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med, 2004; 255: 680-683.

83) Tada H, Inaba S, Pozharitckaia D, Kawashiri MA: Prominent Tendon Xanthomas and Abdominal Aortic Aneurysm Associated with Cerebrotendinous Xanthomatosis Identified Using Whole Exome Sequencing. Intern Med, 2018; 57: 1119-1122.

84) Souto MJS, Almeida-Santos MA, Ferreira EJP, Gonçalves LFG, Oliveira JLM, Sousa ACS: Spontaneous Coronary Artery Dissection in a Patient with Cerebrotendinous Xanthomatosis. Arq Bras Cardiol, 2020; 115: 18-21.

85) Potkin BN, Hoeg JM, Connor WE, Salen G, Quyumi AA, Brush JE Jr, Roberts WC, Brewer HB Jr: Aneurysmal coronary artery disease in cerebrotendinous xanthomatosis. Am J Cardiol, 1988; 61: 1150-1152.

86) Dotti MT, Mondillo S, Plewnia K, Agricola E, Federico A: Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum. J Neurol, 1998; 245: 723-726.

87) Kawabata M, Kuriyama M, Mori S, Sakashita I, Osame M: Pulmonary manifestations in cerebrotendinous xanthomatosis. Intern Med, 1998; 37: 922-926.

88) Guyant-Maréchal L, Verrips A, Girard C, Wevers RA, Zijlstra F, Siermans E, Vera P, Campion D, Hannequin D: Unusual cerebrotendinous xanthomatosis with fronto-temporal dementia phenotype. Am J Med Genet A, 2005; 139A: 114-117.

89) Mukaino A, Tsuda M, Yamashita S, Kosaka T, Wada K, Ando Y: Cerebrotendinous xanthomatosis presenting with extensive cerebral cortex symptoms: A case report. Clin Neurol Neurosurg, 2018; 174: 217-219.

90) Rubio-Agusti I, Kojovic M, Edwards MJ, Murphy E, Chandrahsarke HS, Lachmann RH, Bhatia KP: Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord, 2012; 27: 1769-1774.

91) Mignarri A, Rossi S, Ballerini M, Gallus GN, Del Puppo M, Galluzzi P, Federico A, Dotti MT: Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol, 2011; 258: 783-790.

92) Siebner HR, Berndt S, Conrad B: Cerebrotendinous xanthomatosis without tendon xanthomas mimicking Marinesco-Sjögren syndrome: a case report. J Neurol Neurosurg Psychiatry, 1996; 60: 582-585.

93) Ly H, Bertorini TE, Shah N: An adult male with progressive spastic paraparesis and gait instability. J Clin Neuromuscul Dis, 2014; 16: 98-103.

94) Alhariri A, Hamilton K, Oza V, Cordero K, Sobreira NL, Malloy M, Slavotinek A: Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment. Am J Med Genet A, 2017; 173: 2275-2279.

95) Su CS, Chang WN, Huang SH, Liu CC, Pan TL, Lu CH, Chuang YC, Huang CR, Tsai NW, Hsieh MJ, Chang CC: Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord, 2010; 25: 452-458.

96) Kirmi O, Murphy E, Carecchio M, Sulkin T, Rankin J, Robertson F: Teaching neuroimages: progressive asymmetric parkinsonism and tendon xanthomas. Neurology, 2011; 77: e97-98.

97) Posada IJ, Ramos A: Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord, 2011; 17: 570-572.

98) Lagarde J, Roze E, Apartis E, Pothalid D, Sedel F, Couvert P, Vidailhet M, Degos B: Myoclonus and dystonia in cerebrotendinous xanthomatosis. Mov Disord, 2012; 27: 1805-1810.

99) Yoshinaga T, Sekijima Y, Koyama S, Maruyama K, Yoshida T, Kato T, Ikeda S: Clinical and radiological findings of a cerebrotendinous xanthomatosis patient with a novel p.A335V mutation in the CYP27A1 gene. J Intern Med, 2014; 53: 2725-2729.

100) Szlago M, Gallus GN, Schenone A, Patiño ME, Sfao Z, Rifa A, Da Pozzo P, Cardaioli E, Dotti MT, Federico A: The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Mov Disord, 2014; 53: 570-572.

101) Dutta AK, Danda S, Muthusamy K, Alexander M, Sudhakar SV, Hansdak S, Bandyopadhyay R, Bakhya
Shree GB, Rekha L: Cerebrotendinous xanthomatosis: Possibility of founder mutation in CYP27A1 gene (c.526delG) in Eastern Indian and Surinamese population. Mol Genet Metab Rep, 2015; 3: 33-35

102) Isenhardt K, Schmitt R, Nagel A, Drach L, Scholte W: Inherited cholesterol lipidosis: cerebrotendinous xanthomatosis (van Bogaert Scherer Epstein disease). A clinicopathological study. Clin Neuropathol, 2005; 24: 276-283

103) Stelten BML, de Warrenburg BPC, Wevers RA, Verrrips A: Movement disorders in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord, 2019; 58: 12-16

104) Mignarri A, Falcini M, Vella A, Giorgio A, Gallus GN, Del Puppo M, Vattimo A, Federico A, Dotti MT: Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord, 2012; 18: 99-101

105) Schotsmans K, De Cauwer H, Baets J, Ceyssens S, van den Hauwe L, Deconinck T, Helsen G: Cerebrotendinous xanthomatosis presenting with asymmetric parkinsonism: a case with I-123-FP-CIT SPECT imaging. Acta Neurol Belg, 2012; 112: 287-289

106) Ohnishi A, Yamashita Y, Goto I, Kuroiwa Y, Murakami S, Ikeda M: De- and remyelination and onion bulb in cerebrotendinous xanthomatosis. Acta Neuropathol, 1979; 45: 43-45

107) Argov Z, Soffer D, Eisenberg S, Zimmerman Y: Chronic demyelinating peripheral neuropathy in cerebrotendinous xanthomatosis. Ann Neurol, 1986; 20: 89-91

108) Verrrips A, van Engelen BG, ter Laak H, Gabreëls-Festen A, Janssen A, Zwarts M, Wevers RA, Gabreëls FJ: Cerebrotendinous xanthomatosis. Controversies about nerve and muscle: observations in ten patients. Neuromuscul Disord, 2000; 10: 407-414

109) Pilo B, de Blas G, Sobrido MJ, Navarro C, Grandas F, Barrero FJ, Moya MA, Jimenez-Escrig A: Neuropsychological study in cerebrotendinous xanthomatosis. Muscle Nerve, 2011; 43: 531-536

110) Wang Z, Yuan Y, Zhang W, Zhang Y, Feng L: Cerebrotendinous xanthomatosis with a compound heterozygote mutation and severe polynuropathy. Neuropathology, 2007; 27: 62-66

111) Hashimoto T, Sennari Y, Okada K, Adachi H: Cerebrotendinous Xanthomatosis with Nodular-hypertrophy of the Lumbosacral Roots. Intern Med, 2018; 57: 1669-1670

112) Federico A, Dotti MT, Volpi N: Muscle mitochondrial changes in cerebrotendinous xanthomatosis. Ann Neurol, 1991; 30: 734-735

113) Dotti MT, Manneschi L, Federico A: Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis. J Neurol Sci, 1995; 129: 106-108

114) Arlazoroff A, Roitberg B, Werber E, Shidlo R, Berginer VM: Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia, 1991; 32: 657-661

115) Koyama S, Kawanami T, Tanji H, Arawaka S, Wada M, Saito N, Kato T: A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosci, 2012; 114: 1021-1023

116) Pedroso JL, Pinto WB, Souza PV, Santos LT, Abud IC, Avelino MA, Barsottini OG: Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis. Epilepsy Behav, 2012; 24: 380-381

117) Larson A, Weisfeld-Adams JD, Benke TA, Bonnen PE: Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability. JIMD Rep, 2017; 35: 1-5

118) Berginer VM, Radwan H, Korczyn AD, Kott E, Salen G, Shefer S: EEG in cerebrotendinous xanthomatosis (CTX). Clin Electroencephalogr, 1982; 13: 89-96

119) Wakamatsu N, Hayashi M, Kawai H, Kondo H, Gotoda Y, Nishida Y, Kondo R, Tsuji S, Matsumoto T: Mutations producing premature termination of translation and an amino acid substitution in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis associated with parkinsonism. J Neurol Neurosurg Psychiatry, 1999; 67: 195-198

120) Catarino CB, Vollmar C, Küpper C, Seelos K, Gallenmüller C, Bartkiewicz J, Biskup S, Hörttigel K, Klopopstock T: Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment. J Neurol, 2018; 265: 388-393

121) Kauffman MA, Gonzalez-Morón D, Consalvo D, Kuchen S: Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. Am J Med Sci, 2012; 343: 332-333

122) Fraidakis MJ: Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry, 2013; 3: e302

123) De Stefano N, Dotti MT, Mortilla M, Federico A: Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain, 2001; 124: 121-131

124) Barkhof F, Verrrips A, Wesseling P, van Der Knaap MS, van Engelen BG, Gabreëls FJ, Keyser A, Wevers RA, Valk J: Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology, 2000; 217: 869-876

125) Ahmed RM, Murphy E, Davagnanam I, Parson M, Schott JM, Mumery C, Rohrer JD, Lachmann RH, Houlden H, Fox NC, Chataway J: A practical approach to diagnosing adult onset leukodystrophies. J Neurol Neurosurg Psychiatry, 2014; 85: 770-781

126) Guererra S, Stromillo ML, Mignarri A, Battaglini M, Marino S, Di Perri C, Federico A, Dotti MT, De Stefano N: Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry, 2010; 81: 1189-1193

127) Mandia, Besson G, Lamari F, Castelnuovo G, Curot J, Duval F, Giral P, Lecerf JM, Roland D, Pierdet H, Douillard C, Nadjar Y: Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol, 2019; 266: 2043-2050

128) Mignarri A, Dotti MT, Federico A, De Stefano N, Battaglini M, Grazzini I, Galluzzi P, Monti L: The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J...
Cerebrotendinous Xanthomatosis

Neurol, 2017; 264: 862-874

129) Embiruçu EK, Otaduy MC, Taneja AK, Leite CC, Kok F, Lucato LT: MR spectroscopy detects lipid peaks in cerebrotendinous xanthomatosis. Am J Neuroradiol, 2010; 31: 1347-1349

130) Migliarri A, Dotti MT, Del Puppo M, Gallus GN, Giorgio A, Cerese A, Monti L: Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation: six-year MRI follow-up. Neuoradiology, 2012; 54: 649-651

131) Ragno M, Di Marzio F, Fuccio C, Pianese L, Cozzolino V, Carboni T, Cinti A, D'Andreamatteo G, Trojano L, Migliarri A, Gallus GN, Dotti MT: Cerebellar hypometabolism with normal structural findings in Cerebrotendinous xanthomatosis. A case report. Clin Neurol Neurosurg, 2015; 139: 221-223

132) Caroppo P, D'Agata F, Migliarri A, Stromillo ML, Dotti MT, Mongini T: Brain metabolism changes after therapy with chenodeoxycholic acid in a case of cerebrotendinous xanthomatosis. Neurol Sci, 2013; 34: 1693-1696

133) Chang CC, Lui CC, Wang JJ, Huang SH, Lu CH, Chen C, Chen CF, Tu MC, Huang CW, Chang WN: Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurol, 2010; 10: 59

134) Seidel S, Kasprian G, Prayer D, Kress M, Sycha T, Auff E: Visualisation of treatment response in a case of cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry, 2011; 82: 703-704

135) Soffer D, Benharroch D, Berginer V: The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol, 1995; 90: 213-220

136) Kato H, Kayabu S, Aoki S, Tamai T, Sugawa M, Watanabe M, Shiraiishi T: An autopsy case of gallbladder cancer developing in a Japanese man with cerebrotendinous xanthomatosis: genetic analysis of the sterol 27-hydroxylase and p53 genes. Pathology, 2003; 35: 141-144

137) Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A: Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol, 2008; 255: 839-842

138) Isenhardt K, Schmitt R, Nagel A, Drach L, Schlote W: Inherited cholesterol lipidosis: cerebrotendinous xanthomatosis (van Bogaert Scherer Epstein disease). A clinicopathological study. Clin Neuropathol, 2005; 24: 276-283

139) Wallon D, Guyant-Maréchal L, Laquerrière A, Wevers RA, Martinaud O, Kluijtmans LA, Yntema HG, Saugier-Veber P, Hannequin D: Clinical imaging and neuropathological correlations in an unusual case of cerebrotendinous xanthomatosis. Clin Neuropathol, 2010; 29: 361-364

140) Tokimura Y, Kuriyama M, Arimura K, Fujiyama J, Osame M: Electrophysiological studies in cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry, 1992; 55: 52-55

141) Mondelli M, Rossi A, Scarpini C, Dotti MT, Federico A: Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. Arch Neurol, 1992; 49: 469-475

142) Berginer VM, Gross B, Morad K, Kfir N, Morkos S, Aaref S, Falik-Zaccai TC: Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics, 2009; 123: 143-147

143) Cruysberg JR, Wevers RA, Tolboom JJ: Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmod, 1991; 112: 606-607

144) Sundaram SS, Bove KE, Lovell MA, Sokol RJ: Mechanisms of disease: Inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol, 2008; 5: 456-468

145) Clayton PT: Disorders of bile acid synthesis. J Inherit Metab Dis, 2011; 34: 593-604

146) Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med, 2007; 4: 214-225

147) Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA: Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb, 2018; 25: 783-789

148) Salen G, Batta AK, Tint GS, Shefer S: Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholesterol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Metabolism, 1994; 43: 1018-1022

149) Verrips A, Wevers RA, Van Engelen BG, Keyser A, Wolthers BG, Barkhof F, Stalenhoef A, De Graaf R, Janssen-Zijlstra F, Van Spreeken A, Gabriëls FJ: Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism, 1999; 48: 233-238

150) Kuriyama M, Tokimura Y, Fujiyama J, Utsatu Y, Osame M: Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci, 1994; 125: 22-28

151) Huijdekoper HH, Vaz FM, Verrips A, Bosch AM: Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment. Eur J Pediatr, 2016; 175: 143-146

152) Ellis E, Axelsson M, Abrahamsson A, Eggertsen G, Thörne A, Nowak G, Ericzon BG, Björkhem I, Einarsson C: Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology, 2003; 38: 930-938

153) Setchell KD, Heubi JE: Defects in bile acid biosynthesis—diagnosis and treatment. J Pediatr Gastroenterol Nutr, 2006; 43: S17-22

154) Batta AK, Salen G, Tint GS: Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. Metabolism, 2004; 53: 556-562

155) Lewis B, Mitchell WD, Marenah CB, Cortese C, Reynolds EH, Shakir R: Cerebrotendinous Xanthomatosis. Am J Pediatr, 1991; 112: 606-607

156) Luyckx E, Eyskens F, Simons A, Beckx K, Van West D, Dhar M: Long-term follow-up on the effect of combined...
therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. Clin Neurol Neurosurg, 2014; 118: 9-11

157) Mimura Y, Kuriyama M, Tokimura Y, Fujiyama J, Osame M, Takesako K, Tanaka N: Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. J Neurol Sci, 1993; 114: 227-230

158) Ito S, Kuwabara S, Sakakibara R, Oki T, Arai H, Oda S, Hattori T: Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci, 2003; 216: 179-182

159) Dotti MT, Lütjohann D, von Bergmann K, Federico A: Normalisation of serum cholesterol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis. Neurol Sci, 2004; 25: 185-191

160) Matysik S, Orsó E, Black A, Ahrens N, Schmitz G: Monitoring of 7α-hydroxy-4-cholesten-3-one during therapy of cerebrotendinous xanthomatosis: a case report. Chem Phys Lipids, 2011; 164: 530-534

161) Berginer VM, Salen G: LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis. J Neurol Sci, 1994; 121: 229-232

162) Selva-O’Callaghan A, Bardes I, Jacas C, Jubany L, Lorenzo-Bosquet C, Cuberas-Borrós G, Vilarde-Tarres M: SPECT imaging for brain improvement quantification in a patient with cerebrotendinous xanthomatosis. Clin Nucl Med, 2011; 36: 38-39

163) Amador MDM, Masingue M, Debs R, Lamari F, Perlberg V, Roze E, Degos B, Mochel F: Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes. J Inherit Metab Dis, 2018; 41: 799-807

164) DeBarber AE, Kalfon L, Fedida A, Fleisher Sheffer V, Ben Haroush S, Chasnyk N, Shuster Biton E, Mandel H, Jeffries K, Shinwell ES, Falik-Zaccar TC: Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment. J Lipid Res, 2018; 59: 2214-2222
Supplementary Table 1. Allele frequencies of CYP27A1 variants according to Exome Aggregation Consortium database (version 0.3)

| variant     | AFR   | AMR   | EAS   | FIN   | NFE   | SAS   |
|-------------|-------|-------|-------|-------|-------|-------|
| p.G145=     | 0.00000 | 0.00000 | 0.00040 | 0.00000 | 0.00000 | 0.00000 |
| p.A216P     | 0.00000 | 0.00000 | 0.00000 | 0.00000 | 0.00004 | 0.00000 |
| p.T339M     | 0.00000 | 0.00000 | 0.00010 | 0.00000 | 0.00002 | 0.00007 |
| p.R395C     | 0.00010 | 0.00020 | 0.00000 | 0.00030 | 0.00020 | 0.00006 |
| p.R405W     | 0.00000 | 0.00009 | 0.00000 | 0.00000 | 0.00000 | 0.00006 |
| p.R405Q     | 0.00010 | 0.00009 | 0.00050 | 0.00000 | 0.00004 | 0.00000 |
| p.R474W     | 0.00000 | 0.00000 | 0.00000 | 0.00000 | 0.00002 | 0.00000 |
| p.R474Q     | 0.00000 | 0.00000 | 0.00010 | 0.00000 | 0.00002 | 0.00000 |
| c.1184+1G > A | 0.00000 | 0.00000 | 0.00000 | 0.00000 | 0.00006 | 0.00070 |
| c.1263+1G > A | 0.00000 | 0.00009 | 0.00010 | 0.00000 | 0.00007 | 0.00000 |

AFR: African; AMR: Admixed American; EAS: East Asian; FIN: Finnish; NFE: Non-Finnish European; SAS: South Asian.